Naldemedine - Shionogi

Drug Profile

Naldemedine - Shionogi

Alternative Names: Rizmoic; S-297995; Symproic

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shionogi
  • Developer Purdue Pharma; Shionogi
  • Class Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation

Most Recent Events

  • 12 Oct 2017 Launched for Constipation in USA (PO)
  • 11 Oct 2017 National Hospital Organization Takasaki General Medical Center plans a clinical trial for Constipation in Japan(UMIN000029459)
  • 30 Mar 2017 Registered for Constipation in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top